Novartis Pharma GmbH (Batch release)
UkraineAll drugs from this manufacturer
-
The drug is used as add-on therapy for the treatment of severe allergic asthma (in adults and children from 6 years of age), chronic rhinosinusitis with nasal polyps (in adults), and chronic spontaneous urticaria (in adults and adolescents from 12 years of age).
Dosage form: solution for injection
Active substance Dosage omalizumab 75 mg/0.5 ml ATC: R03DX05
-
The drug is used as add-on therapy for the treatment of severe allergic asthma (in adults and children from 6 years of age), chronic rhinosinusitis with nasal polyps (in adults), and chronic spontaneous urticaria (in adults and adolescents from 12 years of age).
Dosage form: solution for injection
Active substance Dosage omalizumab 150 mg/ml ATC: R03DX05